We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
Mental Health Commission, St. Martin’s House, Waterloo Road, Dublin, Ireland
*
*Address for correspondence: Dr Fionnuala O’Loughlin., MRCPsych, Mental Health Commission, St. Martin’s House, Waterloo Road, Dublin 4, Ireland. (Email: fionnuala.oloughlin@mhcirl.ie)
An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
References
A Vision for Change (2006). Report of the Expert Group on Mental health Policy. Government Publication Office: Dublin.Google Scholar
Barnes, T, Shingleton-Smith, A, Paton, C (2009). Antipsychotic long-acting injections: prescribing practice in the UK. The British Journal of Psychiatry195, s37–s42.CrossRefGoogle Scholar
Baldessarini, R, Leahy, L, AArcona, S, Gause, D, Zhang, W, Hennen, J (2007). Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatric Services58, 85–91.Google Scholar
Blanco, C, Laje, G, Olfson, M, Marcus, S, Pincus, H (2002). Trends in the treatment of bipolar disorder by outpatient psychiatrists. American Journal of Psychiatry159, 1005–1010.Google Scholar
British Medical Association & Royal Pharmaceutical Society of Great Britain (2005). British National Formulary, 50th edn. BMA & Royal Pharmaceutical Society of Great Britain: London.Google Scholar
Brown, S (1997). Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry171, 502–508.Google Scholar
Brown, S, Kim, M, Mitchell, C, Inskip, H (2010). Twenty-five year mortality of a community cohort with schizophrenia. British Journal of Psychiatry196, 116–121.Google Scholar
Clarke, AF, Holden, NL (1987). The persistence of prescribing habits: a survey and follow-up of prescribing to chronic hospitals in–patients. The British Journal of Psychiatry150, 88–91.Google Scholar
Connolly, M, Kelly, C (2005). Lifestyle and physical health in schizophrenia. Advances in Psychiatric Treatment11, 125–132.CrossRefGoogle Scholar
Connolly, A, Rogers, P, Taylor, D (2007). Antipsychotic prescribing quality and ethnicity – a study of hospitalised patients in south east London. Journal of Psychopharmacology21, 191–197.Google Scholar
Correll, C, Rummel-Klugr, C, Corves, C, Kane, J, Leucht, S (2009). Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomised controlled trials. Schizophrenia Bulletin35, 443–457.CrossRefGoogle Scholar
Dunbar, GC, Perra, MH, Jenner, FA (1989). Patterns of benzodiazepine use in Great Britain as measured by a general population survey. The British Journal of Psychiatry155, 836–841.Google Scholar
Essock, S, Covell, N, Leckman-Westin, E, Lieberman, J, Sederer, L, Kealey, E, Finnerty, M and members of the Scientific Committee (2009). Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. Psychiatric Services60, 1595–1602.Google Scholar
Essock, SM, Schooler, NR, Stroup, TS, McEvoy, J, Rojas, I, Jackson, C, Covell, N, The Schizophrenia Trials Network (2011). Effectiveness of switching from antipsychotic polypharmacy to monotherapy. American Journal of Psychiatry168, 702–708.Google Scholar
Finnerty, S (2009). An audit of benzodiazepine and hypnotic prescribing in Irish in-patient psychiatric units. Irish Psychiatrist10, 238–240.Google Scholar
Finnerty, S (2011). An audit of antipsychotic prescribing in Irish in-patient psychiatric units. Irish Psychiatrist12, 26–27.Google Scholar
Fisher, CE, Cohen, C, Forest, L, Schweizer, T, Wasylenki, D (2011). Psychotropic medication use in Canadian long-term patients referred for psychogeriatric consultation. Canadian Geriatrics Journal14, 73–77.Google Scholar
Grech, P, Taylor, D (2012). Long-term antipsychotic polypharmacy: how does it start, and why does it continue?Therapeutic Advances in Psychopharmacology2, 5–11.Google Scholar
Hallahan, BP, Murray, IT, McDonald, C (2009). Benzodiazepine and hypnotic prescribing in an acute adult psychiatric in-patient unit. Psychiatric Bulletin33, 12–14.Google Scholar
Harrington, M, Paton, C, Okocha, C, Duffett, R, Sensky, T (2002). The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bulletin26, 414–418.Google Scholar
Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D (2012). Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to Clozapine initiation. The British Journal of Psychiatry201, 481–485.CrossRefGoogle ScholarPubMed
Jorm, AF, Grayson, D, Creasy, H, Waite, L, Broe, G (2000). Long-term benzodiazepine use by elderly people living in the community. Australian and New Zealand Journal of Public Health24, 7–10.Google Scholar
Joukamaa, M, Heliovaara, M, Knekt, P, Aromaa, A, Raitasalo, R, Lehtinen, V (2006). Schizophrenia, neuroleptic medication and mortality. The British Journal of Psychiatry188, 122–127.Google Scholar
Kirby, M, Denihan, A, Bruce, I, Radic, A, Coakley, D, Lawlor, B (1999). Benzodiazepine use among the elderly in the community. International Journal of Geriatric Psychiatry14, 280–284.Google Scholar
Kogut, SJ, Yam, F, Dufresene, R (2005). Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off-label dosages. Journal of Managed Care Pharmacy11, 17–24.Google Scholar
Mental Health Act (2001). Government of Ireland (2001) Mental Health Act. Dublin: Stationery Office.Google Scholar
National Institute for Clinical Excellence (2010). The NICE Guideline on core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Guideline No 82, NICE: London.Google Scholar
Noir, T (2008). High-dose and combination antipsychotic prescribing in a high security hospital. The British Journal of Psychiatry.Google Scholar
Patrick, V, Schleifer, S, Nurenberg, J, Gill, K (2006). An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatric Services57, 21–23.Google Scholar
Paton, C, Barnes, T, Cavanagh, MR, Taylor, D, Lelliott, P, POMH-UK Project Team (2008). High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by P.R.N. prescribing. The British Journal of Psychiatry192, 435–439.Google Scholar
Petitjean, S, Ladewig, D, Meier, C, Amrein, R, Wiesbeck, G (2007). Benzodiazepine prescribing to the Swiss adult population: results from a national survey of community pharmacies. International Clinical Psychopharmacology22, 292–298.Google Scholar
Planning for the Future (1984). The Psychiatric Services – Planning for the Future. Report of a Study Group on the Development of the Psychiatric Services. Stationery Office: Dublin.Google Scholar
Royal College of Psychiatrists (2006). Consensus statement on high dose antipsychotic medication. Council Report CR 138, Royal College of Psychiatrists.Google Scholar
Royal College of Psychiatrists (2012). National Audit of Schizophrenia Recommendations. Royal College of Psychiatrists: London.Google Scholar
Ryan, MCM, Collins, P, Thakore, JH (2003). Impaired fasting glucose tolerance in first episode, drug naïve patients with schizophrenia. American Journal of Psychiatry160, 284–289.Google Scholar
Summers, J, Brown, KW (1998). Benzodiazepine prescribing in a psychiatric hospital. Psychiatric Bulletin22, 480–483.Google Scholar
Taylor, D, Paton, C, Kapur, S (editors) (2012). Maudsley Prescribing Guidelines in Psychiatry, 11th edn. Wiley-Blackwell.Google Scholar
Tiihonen, J, Lonnqvist, J, Wahlbeck, K, et al. (2009). 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN 11 study). Lancet374, 620–627.Google Scholar
Waddington, JL, Joussef, HA, Kinsella, A (1998). Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. The British Journal of Psychiatry173, 325–329.Google Scholar